During a recent roundtable, Adva Biotechnology CEO, Ohad Karnielli and other industry leaders from around the globe gathered for what became an incredibly candid examination of automation's true value proposition in cell therapy production. The conversation quickly moved beyond typical buzzwords, directly addressing the core question: when does automation actually deliver tangible ROI versus theoretical efficiency?

Enabling Digitization in Cell & Gene Therapy

What's Stopping You Automating Your Cell Therapy Processes Right Now?

The cell and gene therapy industry faces a stark reality.

As investment dollars freeze and purchasing decisions face unprecedented scrutiny, every deal now carries the weight of company survival. Traditional sales approaches that worked in the abundance of 2021 are failing spectacularly in 2025's harsh reality.

Pipeline opportunities are narrowing, competition is intensifying. As one industry leader aptly noted, "The number of customers we're all going after is seemingly shrinking, while the number of competitors has increased. The market is way more competitive, and ABM is probably more important than it's ever been."